

OCT. 19. 2004 5:02PM

(4) FISH&RICHARDSON\_6175428906

RECEIVED  
CENTRAL FAX CENTER NO. 3407 P. 1

OCT 19 2004

Attorney's Docket No.: 13751-046US1  
Client's Ref. No.: A088 US

**OFFICIAL COMMUNICATION FACSIMILE:**

**OFFICIAL FAX NO: (703) 872-9306**

Number of pages including this page 5

Applicant : Chris Polman  
Serial No. : 09/926,693  
Filed : February 1, 2002

Art Unit : 1614  
Examiner : Phyllis G. Spivack


Title : Use of Riluzole for the Treatment of Multiple Sclerosis

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We would like to confirm the personal interview with Examiner Spivack scheduled for tomorrow, Wednesday, October 20, 2004, at 2 PM. Margo H. Furman, Ph.D., and the undersigned will attend the interview with Examiner Spivack. We have attached a set of proposed amended claims to discuss at the interview.

Respectfully submitted,

Date: October 19, 2004

  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Fax: (617) 542-8906

20959145.doc

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (617) 542-5070 to arrange for its return. Thank you.

Applicant : Chris Polman  
Serial No. : 09/926,693  
Filed : February 1, 2002  
Page : 2 of 5

Attorney's Docket No.: 13751-046US1 / A088 US

**PROPOSED CLAIMS**  
**DRAFT FOR EXAMINER**

1. (Canceled)
2. (Currently amended) A method for the treatment of multiple sclerosis, comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of riluzole 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.
3. (Previously presented) The method of claim 2 wherein said pharmaceutical composition comprises a pharmaceutically effective carrier.
4. (Previously presented) The method of claim 2 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent.
5. (Previously presented) The method of claim 4 wherein said additional agent is selected from the group consisting of interferon beta-1a, interferon beta-1b, and copaxone.
6. (Currently amended) The method according to claim 2 wherein the amount of riluzole 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 10 and about 500 mg per day.
7. (Currently amended) The method of claim 6 wherein the amount of riluzole 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 50 and about 250 mg per day.
8. (Currently amended) A method for treating a patient suffering from multiple sclerosis comprising the step of administering a pharmaceutical composition comprising riluzole 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof in an amount effective to inhibit,

minimize or delay the development of spinal cord atrophy associated with multiple sclerosis.

Applicant : Chris Polman  
Serial No. : 09/926,693  
Filed : February 1, 2002  
Page : 3 of 5

Attorney's Docket No.: 13751-046US1 / A088 US

9. (Previously presented) The method of claim 8 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent selected from the group consisting of interferon beta-lb, interferon beta-la, and copaxone.

10. (Currently amended) A method for the treatment of a patient suffering from multiple sclerosis comprising the steps of administering to said patient:

a. a therapeutically effective amount of a pharmaceutical composition comprising ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof; and

b. a therapeutically effective amount of a pharmaceutical composition selected from the group consisting of interferon beta-lb, interferon beta-la, and copaxone.

11. (Currently amended) A method for the treatment of a patient suffering from primary progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

12. (Previously presented) The method of claim 11 further comprising the administration of a therapeutically effective amount of interferon beta-lb, copaxone and interferon beta-la.

13. (Currently amended) A method for the treatment of a patient suffering from secondary-progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

14. (Currently amended) A method for the treatment of a patient suffering from relapsing-remitting multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

Applicant : Chris Polman  
Serial No. : 09/926,693  
Filed : February 1, 2002  
Page : 4 of 5

Attorney's Docket No.: 13751-046US1 / A088 US

15. (Previously presented) The method of claim 2, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.

16. (Previously presented) The method of claim 2, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

17. (Previously presented) The method of claim 8, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.

18. (Previously presented) The method of claim 8, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

19. (Previously presented) The method of claim 10, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.

20. (Previously presented) The method of claim 10, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

21. (Previously presented) The method of claim 11, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.

22. (Previously presented) The method of claim 11, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

23. (Previously presented) The method of claim 13, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.

24. (Previously presented) The method of claim 13, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

Applicant : Chris Polman  
Serial No. : 09/926,693  
Filed : February 1, 2002  
Page : 5 of 5

Attorney's Docket No.: 13751-046US1 / A088 US

25. (Previously presented) The method of claim 14, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.

26. (Previously presented) The method of claim 14, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.